NuVasive (NASDAQ:NUVA) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of NuVasive (NASDAQ:NUVA) in a report issued on Thursday morning, AnalystRatings.com reports.

A number of other analysts have also issued reports on the company. BTIG Research reissued a buy rating and issued a $65.00 target price on shares of NuVasive in a research report on Monday, July 1st. Cantor Fitzgerald reissued a hold rating and issued a $61.00 target price on shares of NuVasive in a research report on Thursday, May 2nd. Morgan Stanley boosted their target price on NuVasive from $57.00 to $67.00 and gave the company an equal weight rating in a research report on Wednesday, July 31st. TheStreet raised NuVasive from a c+ rating to a b rating in a research report on Wednesday, July 31st. Finally, BidaskClub raised NuVasive from a sell rating to a hold rating in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $66.14.

Shares of NUVA stock traded up $0.23 during trading on Thursday, hitting $66.07. 349,536 shares of the stock traded hands, compared to its average volume of 579,950. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of 29.63, a P/E/G ratio of 2.22 and a beta of 1.14. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.60 and a quick ratio of 1.99. The firm’s fifty day moving average price is $59.17. NuVasive has a 52-week low of $43.51 and a 52-week high of $72.41.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, July 30th. The medical device company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.07. The company had revenue of $292.11 million for the quarter, compared to analyst estimates of $290.59 million. NuVasive had a return on equity of 15.09% and a net margin of 4.65%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.58 earnings per share. On average, equities analysts forecast that NuVasive will post 2.32 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in NuVasive by 27.5% during the second quarter. Bank of Montreal Can now owns 7,186 shares of the medical device company’s stock worth $420,000 after purchasing an additional 1,550 shares in the last quarter. Prudential Financial Inc. raised its holdings in NuVasive by 6.4% during the second quarter. Prudential Financial Inc. now owns 35,136 shares of the medical device company’s stock worth $2,057,000 after purchasing an additional 2,120 shares in the last quarter. FineMark National Bank & Trust purchased a new position in NuVasive during the second quarter worth about $208,000. Acadian Asset Management LLC purchased a new position in NuVasive during the second quarter worth about $45,000. Finally, Signition LP raised its holdings in NuVasive by 89.2% during the second quarter. Signition LP now owns 31,563 shares of the medical device company’s stock worth $1,848,000 after purchasing an additional 14,877 shares in the last quarter.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Recommended Story: Blockchain

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.